Bocanegra Mildred, Seijas Alberto, González Yibirín María
Natera Guarapo Dental Group, Caracas, Venezuela.
Policlinical Institute, Caracas, Venezuela.
Curr Ther Res Clin Exp. 2005 May;66(3):172-80. doi: 10.1016/j.curtheres.2005.06.007.
Nimesulide is a nonsteroidal, anti-inflammatory drug that hasbeen used for a wide range of acute and chronic pain. A once-daily formulation of nimesulide is now commercially available, but its effectiveness in pain management after dental surgery has not been assessed.
The aim of this study was to assess the analgesic effectiveness and tolerability of oral treatment with once-daily nimesulide versus ibuprofen q6h over 24 hours in patients with postoperative pain associated with surgical extraction of an impacted third molar.
This 24-hour, double-blind, randomized, double-dummy, parallel-groupstudy was conducted at a private practice in Caracas, Venezuela. Patients aged between 12 and 60 years with moderate to severe pain after extraction of an impacted third molar were enrolled. Patients were randomized to receive a single dose of nimesulide (300-mg tablet) or ibuprofen (400-mg tablets) q6h for 24 hours. For double-dummy design, patients in the nimesulide group also received ibuprofen placebo tablets, to be taken q6h for 24 hours, and patients in the ibuprofen group received a nimesulide placebo tablet. The primary end points were pain intensity (PI) and pain relief scores over 24 hours. Secondary end points included total pain relief, PI difference (PID), sum of PID (SPID), time to first measurable change in PI (ie, PID ≥ 10 mm), and use of rescue medication (acetaminophen). Patients also rated the treatment's effectiveness as very poor to very good on questioning by the study investigator. Spontaneously reported adverse effects (AEs) were recorded.
Eighty-six patients were enrolled (56 females, 30 males), with 43 patientsper treatment group (mean age: nimesulide group, 25.2 years; ibuprofen group, 24.2 years). The baseline characteristics were statistically similar between the 2 groups. Compared with baseline, mean PI scores were significantly lower in both treatment groups at all time points throughout the study (P < 0.001). Mean PI scores were significantly lower in the nimesulide group compared with the ibuprofen group at 15 and 45 minutes and 1 hour after study drug administration (P ≤ 0.049). Time to first measurable change in PI was within the first 15 minutes in 22 patients (52%) in the nimesulide group and in 14 patients (33%) in the ibuprofen group (P = 0.03). Analgesia lasted 24 hours with nimesulide and ibuprofen (PI scores at 24 hours, 9.4 and 3.6, respectively). The mean PR score was significantly lower in the nimesulide group compared with the ibuprofen group at 1 hour after study drug administration (P = 0.049). Compared with baseline, PID and SPID were significantly higher in both treatment groups throughout the study (P < 0.001). Significantly more patients in the nimesulide group than in the ibuprofen group reported that treatment provided effective pain relief (82% vs 73%; P = 0.013). No AEs were reported in either treatment group throughout the study. Use of rescue medication was statistically similar between the nimesulide and ibuprofen groups (38% and 31%, respectively).
In this study of patients with moderate to severe pain afterextraction of impacted third molars, nimesulide and ibuprofen provided effective 24-hour relief. However, the results suggest that the analgesic effect of nimesulide had a faster onset (<15 minutes) and was stronger (based on patient opinion) than that of ibuprofen. Both study drugs were well tolerated.
尼美舒利是一种非甾体类抗炎药,已被用于治疗多种急慢性疼痛。尼美舒利的每日一次剂型现已上市,但尚未评估其在牙科手术后疼痛管理中的有效性。
本研究旨在评估每日一次尼美舒利口服治疗与布洛芬每6小时一次口服治疗在24小时内对因拔除阻生第三磨牙而术后疼痛患者的镇痛效果和耐受性。
本为期24小时的双盲、随机、双模拟、平行组研究在委内瑞拉加拉加斯的一家私人诊所进行。纳入年龄在12至60岁之间、拔除阻生第三磨牙后有中度至重度疼痛的患者。患者被随机分为接受单剂量尼美舒利(300毫克片剂)或布洛芬(400毫克片剂),每6小时一次,共24小时。采用双模拟设计,尼美舒利组患者还接受布洛芬安慰剂片剂,每6小时服用一次,共24小时,布洛芬组患者接受尼美舒利安慰剂片剂。主要终点为24小时内的疼痛强度(PI)和疼痛缓解评分。次要终点包括总疼痛缓解、PI差值(PID)、PID总和(SPID)、PI首次出现可测量变化的时间(即PID≥10毫米)以及急救药物(对乙酰氨基酚)的使用情况。患者还在接受研究调查员询问时将治疗效果评为非常差至非常好。记录自发报告的不良反应(AE)。
共纳入86例患者(56例女性,30例男性),每个治疗组43例患者(平均年龄:尼美舒利组25.2岁;布洛芬组24.2岁)。两组的基线特征在统计学上相似。与基线相比,在整个研究的所有时间点,两个治疗组的平均PI评分均显著降低(P<0.001)。在给予研究药物后15分钟、45分钟和1小时,尼美舒利组的平均PI评分显著低于布洛芬组(P≤0.049)。尼美舒利组22例患者(52%)和布洛芬组14例患者(33%)的PI首次出现可测量变化的时间在最初15分钟内(P = 0.03)。尼美舒利和布洛芬的镇痛作用均持续24小时(24小时时的PI评分分别为9.4和3.6)。在给予研究药物后1小时,尼美舒利组的平均PR评分显著低于布洛芬组(P = 0.049)。与基线相比,在整个研究中两个治疗组的PID和SPID均显著升高(P<0.001)。尼美舒利组报告治疗能有效缓解疼痛的患者显著多于布洛芬组(82%对73%;P = 0.013)。在整个研究中,两个治疗组均未报告AE。尼美舒利组和布洛芬组急救药物的使用在统计学上相似(分别为38%和31%)。
在本对拔除阻生第三磨牙后有中度至重度疼痛患者的研究中,尼美舒利和布洛芬均能提供有效的24小时疼痛缓解。然而,结果表明尼美舒利的镇痛作用起效更快(<15分钟)且更强(基于患者意见)。两种研究药物的耐受性均良好。